logo

Opiant Pharmaceuticals Inc. (OPNT)



Trade OPNT now with
  Date
  Headline
12/20/2017 8:07:47 AM Opiant Announces Significant Financial Developments Related To NARCAN Nasal Spray For Opioid Overdose
12/4/2017 4:08:16 PM Opiant Pharmaceuticals Q1 Loss/share $2.77 Vs. Loss $0.30 Year Ago
10/13/2017 7:06:09 AM Opiant Pharma Q4 Net Loss $0.3 Mln Or $0.17/shr Vs. Loss Of $1.1 Million, Or $0.57/shr Prior Year
10/2/2017 7:11:10 AM Opiant Pharma, Titan Pharma Collaborate To Explore New Approach To Opioid Use Disorder Treatment
9/15/2017 7:02:21 AM Opiant Pharmaceuticals Provides Update On NARCAN Nasal Spray
9/5/2017 7:07:22 AM Opiant Pharmaceuticals Names David O’Toole CFO
8/10/2017 7:08:48 AM Opiant Pharma Unveils Addl. $3.75 Mln Payment From NARCAN Nasal Spray Royalty Monetization
7/19/2017 7:07:54 AM Opiant Pharma Announces Phase I Data For OPNT002 In Development For Treatment Of AUD
6/27/2017 7:02:47 AM Opiant Pharma Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent
3/20/2017 7:04:51 AM Opiant Pharma Begins Phase 2 Clinical Trial Evaluating OPNT001 In Bulimia Nervosa
3/9/2017 7:08:34 AM Opiant Pharma Announces FDA Orange Book Listings For Two New NARCAN Nasal Spray Patents
2/28/2017 7:12:29 AM Opiant Pharma Gets FDA Feedback Supporting Clinical Development Of OPNT002 For Treatment Of Alcohol Use Disorder
12/16/2016 8:10:01 AM Opiant Pharma Q1 Net Loss $601K Or $0.30/shr Vs Loss Of $11.1 Mln Or $6.00 /shr Last Year
10/31/2016 7:09:12 AM Opiant Pharma FY Net Loss $7.814 Mln Or $4.09/shr Vs Loss Of $7.038 Mln Or $3.88/shr Last Year
10/27/2016 7:23:06 AM Opiant Pharma Announces FDA Orange Book Listing For Narcan Nasal Spray Patent